Join
Live feed
·
INSIDERFilingvia Quantisnow
Aclaris Therapeutics Inc. logo

Chief Financial Officer Balthaser Kevin converted options into 2,375 shares and covered exercise/tax liability with 677 shares, increasing direct ownership by 0.91% to 187,453 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ACRS (Aclaris Therapeutics Inc.) and more on Quantisnow.